Oyster Point Pharma EBIT

The latest EBIT for OYST is $-160M as of September 2022. That compares with $-80M in the prior-year period — down 106.2% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Oyster Point Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, OYST's EBIT moved from $-80M to $-160M — a 106.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oyster Point Pharma's operating scale or balance-sheet position.

Against Healthcare companies, OYST currently prints $-160M for EBIT, while the sector average sits near $23B. That is roughly 100.7% below the sector mean. Large gaps often invite a closer look at Oyster Point Pharma's growth, margins, and balance sheet.

A EBIT figure of $-160M for OYST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting OYST's EBIT ($-160M), review year-over-year change from $-80M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.